Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summaryMarketScreener Strategies
OFFRE
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 62.04 USD
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The group usually releases earnings worse than estimated.
  • Based on current prices, the company has particularly high valuation levels.
  • The company benefits from high valuations in earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY25.79%189 092
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
AMGEN17.94%132 756
ABBOTT LABORATORIES20.54%121 136
ELI LILLY AND COMPANY25.89%114 197
SANOFI3.69%109 540
BRISTOL-MYERS SQUIBB COMPAN..0.77%101 584
GLAXOSMITHKLINE15.80%99 260
ASTRAZENECA10.72%92 763
NOVO NORDISK A/S-9.87%89 924
BAYER-25.23%83 828
ALLERGAN PLC17.69%64 939
CELGENE CORPORATION-15.39%61 699
More Results
Financials ($)
Sales 2018 42 371 M
EBIT 2018 13 742 M
Net income 2018 7 016 M
Debt 2018 14 978 M
Yield 2018 2,74%
P/E ratio 2018 27,54
P/E ratio 2019 18,57
EV / Sales 2018 4,82x
EV / Sales 2019 4,57x
Capitalization 189 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MERCK AND COMPANY
Duration : Period : Day
Merck and Company Technical Analysis Chart | MarketScreener
Duration : Period : Week
Merck and Company Technical Analysis Chart | MarketScreener